TD Cowen Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Yaron Werber maintains a Buy rating on Ionis Pharmaceuticals (NASDAQ:IONS) and raises the price target from $54 to $59.
July 23, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Yaron Werber maintains a Buy rating on Ionis Pharmaceuticals and raises the price target from $54 to $59.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100